An observational multicenter study to evaluate the efficacy and safety of degarelix® for prostate cancer in routine clinical practice

Background. Prostate cancer (PCa) is an actual disease and a frequent oncological pathology in men. The main methods of radical treatment of patients with PCa are radical prostatectomy and radiation therapy. Radical prostatectomy s the most commonly used method of therapy in patients with localized PCa. Adjuvant hormone therapy after surgical treatment is the standard method of therapy in patients with the presence of lymph node metastases. At the same time, the standard approach of treatment of patients with metastatic PCa is combination therapy with medical (using of analogues or antagonists of luteinizing hormone-releasing hormone (LHRH) or surgical castration in combination with chemotherapy with docetaxel or new generation antiandrogens (enzalutamide or apalutamide)). Numerous studies have demonstrated the importance of achieving minimum testosterone levels at all stages of drug therapy in patients with PCa. It has also been shown that the use of LHRH analogues may be less effective to the use of LHRH antagonists (degarelix) in relation to the effectiveness of testosterone suppression. Thus, conducting a study aimed at studying the effectiveness of testosterone suppression using LHRH antagonists in various clinical situations and patient populations in real clinical practice is a very actual task.

Aim. To evaluate the effectiveness and safety of castration therapy using degarelix in real clinical practice and in various clinical situations.

Materials and methods. The object of an observational non-interventional study was 132 patients with PCa from 13 cancer centers of Russian Federation who were treated with LHRH antagonist degarelix. The study was non-interventional (observational), retrospectively-prospective, open multicenter and not randomized. In accordance with the design of the study, depending on the clinical situation, patients were divided into 3 groups: group A (n = 52; 39.4 %) – patients with primary metastatic hormone-sensitive PCa, who were shown to undergo combined drug treatment with castration therapy as one of the components; group B (n = 43; 32.6 %) – patients, who underwent combined hormonal and radiation treatment (ADT + radiation therapy); group C (n = 37; 28 %) – patients who underwent surgical treatment (radical prostatectomy with extended PLND) with the presence of metastases in the lymph nodes identified by the results of a morphological examination (pN1).

Results and conclusion. As a result of a non-interventional observational study, high efficacy of androgen-deprivation therapy with the use of degarelix was demonstrated in relation to the suppression of testosterone and PSA in patients with primary metastatic and locally advanced PCa in various clinical situations, as well as low toxicity and satisfactory tolerability of this variant of hormonal treatment.

1. State of oncological care in Russia in 2019. Eds.: А.D. Kaprin, V.V. Starinskiy, A.О. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 239 p. (In Russ.).

2. Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;19:293–7.

3. Crawford E.D. Hormonal therapy in prostate cancer: historical approaches. Rev Urol 2004;6(Suppl 7): S3–11.

4. Gritskevich A.A., Medvedev V.L., Teplov A.A. et al. The current abilities of third-generation luteinizing hormonereleasing hormone antagonists in the treatment of hormone-responsive prostate cancer. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2014;3(6):63–71. (In Russ.).

5. Persson B.E., Olesen T.K., Jensen J.K. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90(3):235–44. DOI: 10.1159/000228832

6. Mongiat-Artus P., Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(10):2171–9. DOI: 10.1517/14656566.5.10.2171

7. Frampton J.E., Lyseng-Williamson K.A. Degarelix. Drugs 2009;69(14):1967–76. DOI: 10.2165/10484080-00000000000000

8. Steinberg M. Degarelix: a gonadotropin releasing hormone antagonist for the management of prostate cancer. Clin Ther 2009;31:2312–31. DOI: 10.1016/j.clinthera.2009.11.009

9. White R., Schwach G., Schteingart C. Degarelix, a unique, sustained-release depot GnRH blocker with a long duration of action. 1st European Multidisciplinary Meeting on Urological Cancers. Barcelona, 24 November 2007. Abstract P92. Available at: http://www.emucbarcelona2007.org/fileadmin/user_upload/downloads/EMUC_Binnen.pdf (accessed 31 July 2012).

10. Gittelman M., Pommerville P.J., Persson B.E. et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008;180(5):1986–92. DOI: 10.1016/j.juro.2008.07.033

11. Van Poppel H., Tombal B., de la Rosette J.J. et al. Degarelix: a novel gonadotropinreleasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54(4):805–13. DOI: 10.1016/j.eururo.2008.04.065

12. Ozono S., Ueda T., Hoshi S. et al. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol 2012;42(6):477–84. DOI: 10.1093/jjco/hys035

13. Klotz L., Boccon-Gibod L., Shore N. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 2008;102(11):1531–8. DOI: 10.1111/j.1464-410X.2008.08183.x

14. Hosseini S.A., Rajabi F., Akbari Sari A. et al. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. Med J Islam Repub Iran 2016;30:317.

15. Sun Y., Xie L., Xu T. et al. Efficacy and safety of degarelix in patients with prostate cancer: results from a phase III study in China. Asian J Urol 2020;7(3):301–8. DOI: 10.1016/j.ajur.2019.09.003

16. Sciarra A., Fasulo A., Ciardi A. et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine 2016;95(27):e3845. DOI: 10.1097/MD.0000000000003845

17. Smith M., Klotz L., Persson B.E. et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel-group phase III trial in patients with prostate cancer. J Urol 2010;184(6):2313–9. DOI: 10.1016/j.juro.2010.08.012

18. European association of urology (EAU) Guidelines on prostate cancer. 2016. MT/W/0001/pdWS/001.

19. Geiges G., Harms T., Rodemer G. et al. Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry. BMC Urol 2015;15122. DOI: 10.1186/s12894-015-0116-4